Marius Andrei Zavalichi

Marius Andrei Zavalichi

Auto-generated profile, based on publicly available information

Marius Andrei Zavalichi

Cardiovascular Diseases Institute "Prof. Dr. George I.M. Georgescu", Iasi, Romania

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MZMarius Andrei Zavalichi
Marius Andrei Zavalichi
INIonut Nistor
Ionut Nistor
ACAlina Chelsău
Alina Chelsău
SZSimona Daniela Zavalichi
Simona Daniela Zavalichi
CGCătălina Marina Arsenescu Georgescu
Cătălina Marina Arsenescu Georgescu
ACAdrian Constantin Covic
Adrian Constantin Covic
Background. Cardiogenic shock is associated with high mortality, despite new strategies for reperfusion therapy. Short‐term circulatory support devices may provide adequate support for appropriate myocardial and organ perfusion. Objectives. This review is aimed at evaluating the impact on survival when using venoarterial extracorporeal membrane oxygenation (V‐A ECMO) in patients with cardiogenic shock due to acute myocardial infarction (AMI). Methods. We performed a systematic review that included studies using V‐A ECMO in patients with cardiogenic shock. Time on ECMO, side effects, and the number of deceased patients, transplanted or upgraded to durable assist devices were analysed. Literature search was done using PubMed/MEDLINE (inception (1969) to January 10, 2019), ProQuest (inception (January 14, 1988) to January 10, 2019), and clinicaltrials.gov (inception (September 12, 2005) to January 10, 2019), by 2 authors. This protocol is registered with PROSPERO (no. CRD42019123982). Results. We included 9 studies with a total of 1,998 adult patients receiving V‐A ECMO for AMI‐induced cardiogenic shock. Survival rate varied from 30.0% to 79.2% at discharge and from 23.2% to 36.1% at 12 months. Time on ECMO varied between 1.96 and 6.0 days. Reported serious adverse events were gastrointestinal bleeding (3.6%) and peripheral complications (8.5%). Conclusion. The use of V‐A ECMO among patients with AMI‐induced cardiogenic shock may provide survival benefits. However, V‐A ECMO treatment effects are inconclusive because of limitations in cohort design and reporting.

20 January 2023 in Archives of Medical Science
Verified
Journal Article
Open access
GIGeorgiana Ionescu
Georgiana Ionescu
MZMarius Andrei Zavalichi
Marius Andrei Zavalichi
CGCătălina Marina Arsenescu Georgescu
Cătălina Marina Arsenescu Georgescu
AMAdelina Mihaescu
Adelina Mihaescu
SZSimona Daniela Zavalichi
Simona Daniela Zavalichi
INIonut Nistor
Ionut Nistor
Introduction: COVID-19 pandemic represents a major worldwide challenge, with a great impact on health systems and economic mechanisms. SARS-CoV-2, the pathogen agent that generates COVID-19, creates a wide variety of organ dysfunctions, from acute respiratory distress syndrome (ARDS) to acute myocardial infarction or pulmonary embolism. Mechanical circulatory support devices such as Extracorporeal Membrane Circulatory Oxygenation (ECMO) have shown their efficacy in maintaining organs perfusion in respiratory and cardiac impairments. With this review, we aimed to assess the impact of ECMO use in COVID-19 patients with ARDS.Material and methods: We performed a systematic review to find the studies using ECMO in COVID-19. Comorbidities, side effects, and survival rate to discharge were analysed. The literature search was done using PubMed/MEDLINE, Web of Science, Embase (Elsevier), the Cochrane Central Register of Controlled Trials (Wiley) and clinicaltrials.gov databases (inception (December 2019) to October 16, 2021), by 2 authors.Results: We included 33 studies from 10 countries with a total of 4.760 patients receiving ECMO for COVID-19. Survival rate varied from 9% to 90,6% at discharge. The most serious adverse events were acute kidney injury (up to 87%), major bleeding (up to 92,1%), strokes or cerebral hemorrhage (up to 34%). Other complications such as pulmonary embolism, peripheral bleeding, or sepsis had a major impact on survival rates.Conclusions: ECMO in COVID-19 patients may be a useful rescue therapy instrument, but due to the great variability of studies and still unknown mechanisms and effects of the SARS-CoV-2, further studies are need to be done.